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ABSTRACT  
Amyloidoses are rare life-threatening diseases caused by protein misfolding of normally soluble 
proteins. The fatal outcome is predominantly due to renal failure and/or cardiac dysfunction. 
Because amyloid fibrils formed by all amyloidogenic proteins share structural similarity, 
amyloidoses may be studied in transgenic models expressing any amyloidogenic protein. Here 
we generated transgenic mice expressing an amyloidogenic variant of human apolipoprotein AII, 
a major protein of high density lipoprotein. According to amyloid nomenclature this variant was 
termed STOP78SERApoAII. STOP78SER-APOA2 expression at the physiological level 
spontaneously induced systemic amyloidosis in all mice with full-length mature STOP78SER-
ApoAII identified as the amyloidogenic protein. Amyloid deposits stained with Congo red, were 
extracellular, and consisted of fibrils of approximately 10 nm diameter. Renal glomerular 
amyloidosis was a major feature with onset of renal insufficiency occurring in mice older than six 
months of age. The liver, heart and spleen were also greatly affected. Expression of STOP78SER-
APOA2 in liver and intestine in mice of the K line but not in other amyloid-laden organs showed 
they present systemic amyloidosis. The amyloid burden was a function of STOP78SER-APOA2 
expression and age of the mice with amyloid deposition starting in two-month old high-
expressing mice that died from six months onwards. Because STOP78SER-ApoAII conserved 
adequate lipid binding capacity as shown by high STOP78SER-ApoAII amounts in high density 
lipoprotein of young mice, its decrease in circulation with age suggests preferential deposition 
into preformed fibrils. Thus, our mouse model faithfully reproduces early-onset hereditary 
systemic amyloidosis and is ideally suited to devise and test novel therapies. 
 
Translational Statement 
Amyloidoses are presently incurable, with fatal outcomes at the fifth to sixth decade. We report 
the first animal model spontaneously developing early onset hereditary systemic amyloidosis. 
These transgenic mice will allow studies of the in vivo mechanisms of amyloidogenesis, which 
should end up in designing new treatments that attack and destroy pre-existing amyloid fibrils. 
These novel treatments may serve for the clinical care of all amyloidoses. In addition, they may 
serve to test gene-silencing therapies aiming to decrease production and plasma concentration of 
the amyloidogenic variant protein resulting in diminished amyloid burden and organ dysfunction, 
thus improving quality of life in patients. 
 
Key words: mouse model; hereditary systemic amyloidosis; glomerular amyloid deposits 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
 4
Introduction 
Amyloidoses are rare life-threatening diseases caused by protein misfolding of normally soluble 
proteins1-4. The misfolded proteins aggregate into insoluble fibrils that accumulate extracellularly 
provoking organ dysfunction. Several criteria permitted identification of 36 amyloidogenic 
proteins: i) Congo red (CR) staining, the gold standard; ii) electron microscopy; iii) X-ray 
diffraction; iv) chemical identification of the amyloid fibril protein by sequence analysis and 
mass spectrometry2,5,6. In immunoglobulin light chain amyloidosis (AL), the most common form 
of clinical amyloidosis, amyloid fibrils are formed from monoclonal immunoglobulin light chains 
(LC’s)1-4; rapid and efficient treatment of the hematological disorder prolongs patient survival7. 
Hereditary systemic amyloidoses are autosomal dominant diseases caused by a mutation in a 
circulating protein that becomes amyloidogenic; the prefix A is added to the name of the parent 
protein identified in amyloid deposits, and in the ensuing amyloidosis2. Intriguingly, several 
hereditary amyloidoses are caused by mutations in apolipoproteins (apo), the protein moieties of 
lipoproteins: apoAI8,9, apoAII10-12, apoCII13, apoCIII14, and by normal apoAIV15. Thus, 
amyloidosis due to variant apoAII is called AApoAII amyloidosis. Reactive amyloidosis occurs 
under inflammatory conditions inducing overproduction of the acute phase protein serum 
amyloid A (SAA). Shutting down SAA synthesis by treating inflammation results in amyloid 
resorbtion16. Despite the great variety of amyloidogenic proteins, amyloidoses share several 
features: i) amyloidogenesis requires a minimal plasma concentration of the amyloidogenic 
protein1-4; ii) specific proteins including glycosaminoglycans (GAG), serum amyloid P-
component (SAP), apoE, apoAI, apoAIV co-aggregate with the fibrils5,6; iii) all amyloid fibrils 
share very similar structures. Obviously, proteins with a particular tertiary structure become 
amyloidogenic: i.e. only a small proportion of immunoglobulin LC’s is amyloidogenic1-4, and 
one type of murine apoAII (mApoAII) provokes amyloidosis in aged senescence-prone mice17-18. 
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The fatal outcome is predominantly due to renal failure and /or cardiac dysfunction1-4, i.e. all 
patients with AApoAII amyloidosis10-12 and approximately 70% of patients with AL amyloidosis7 
are diagnosed with nephrotic syndrome progressing to chronic kidney disease (CKD) and 
ultimately to end-stage renal disease (ESRD). 
To study in vivo amyloidogenesis and devise novel therapies, a good animal model is needed19. 
In most mouse models reactive amyloidosis has been induced by repeated injections of toxic 
inflammatory-stimulating agents (e.g. silver nitrate, casein, lipopolysaccharide) that enhance 
SAA synthesis. The amyloidogenic process is accelerated by additional administration of 
amyloid enhancing factor (AEF, consisting of protein fibrils extracted from amyloid-laden 
murine tissue)20,21. This implies a “seeding process” whereby small amounts of preformed fibrils 
constitute nuclei initiating amyloidogenesis21. Although amyloid deposits regress through SAA 
decrease, a primed state exists upon SAA reinduction22. The usefulness of such models is limited 
because the induction and extent of amyloid deposition are unpredictable, and the spleen is the 
main affected organ21 instead of the kidney in the human disease16. Transgenic mice expressing 
either human interleukin 6 (hIL-6)23,24 or SAA25 spontaneously displayed high SAA 
concentration and renal amyloidosis23. Because the renal disease became less aggressive in 
successive generations and fertility of transgenic mice was low 23, AEF was used to induce rapid 
development of hepatic and splenic amyloidosis24. Transgenic mice with doxycycline-inducible 
SAA expression developed amyloidosis in the spleen and liver after AEF injection and 
independently of prior inflammation25. After doxycycline withdrawal, SAA production decreased 
down to normal and amyloid deposits regressed. Interestingly, reinduction of SAA 
overexpression resulted in rapid amyloid deposition in glomeruli leading to renal failure, while 
minor cardiac amyloid deposits also occurred25. Thus, current murine models overexpressing 
SAA rarely develop spontaneously renal amyloidosis. 
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Animal models for hereditary transthyretin amyloidosis failed to reproduce familial amyloidotic 
polyneuropathy26,27. To our knowledge, other models of hereditary amyloidoses have not been 
reported. Thus, an efficient animal model of hereditary systemic amyloidosis resembling the 
human pathology was needed, with early onset and kidney targeting of amyloidosis. To create 
such a model, we chose as a transgene APOA2 carrying the STOP78 to Serine mutation resulting 
in production of a carboxyl terminal 21 amino acid extension of mature human apoAII 
(hApoAII); STOP78SER-APOA2 carriers present with systemic amyloidosis, with major amyloid 
deposits in kidney glomeruli provoking renal failure10. Five different single nucleotide changes 
resulting in four different amino acid replacements of the STOP codon, have been described in 
patients with the same renal amyloidosis10-12,28,29 (Supplementary Table S1). Because all 
amyloidogenic proteins identified thus far form amyloid fibrils with great structural similarities1-
4
, transgenic mice expressing any amyloidogenic protein should be good models to study the 
mechanisms of amyloidogenesis and to devise and test treatments for all amyloidoses1-4. 
According to the established amyloid nomenclature, the hApoAII variant is termed STOP78SER-
ApoAII in plasma and AApoAII in amyloid deposits2. 
 
RESULTS 
Generation of STOP78SER-ApoAII-transgenic mice  
The STOP78SER-APOA2 transgene was obtained by site-directed mutagenesis of the 3-kilobase 
genomic clone of the APOA2 gene (2911/12045) comprising the endogenous promoter30 ensuring 
STOP78SER-ApoAII production mainly in the liver31 and a little in the intestine32 
(Supplementary Figure S1). Two transgenic lines with plasma concentrations of STOP78SER-
ApoAII either at the physiological level of normal hApoAII (K line) or 2 times higher (F line) 
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spontaneously developed systemic amyloidosis. The Y line with plasma STOP78SER-ApoAII 
concentration 2-3 times lower than normal did not develop amyloidosis. To study solely the 
effects of STOP78SER-ApoAII, all lines were backcrossed onto the apoAII-knock-out 
(KO)/C57BL/6 background32,33. Importantly, 100% of K and F mice developed systemic 
amyloidosis in most organs tested (Figures 1 and 2). Hemizygous F mice (STOP78SER-
ApoAII: 60-70 mg/dl) and K mice (STOP78SER-ApoAII: 30-40 mg/dl) developed amyloidosis 
from 2 and 3-4 months onwards, respectively. Amyloidosis progressed more rapidly in the 
homozygous states, homozygous F mice often dying aged 6-7 months. Macroscopically, the liver, 
heart and spleen were classified in four severity stages (Supplementary Figure S2a,b), 
(Supplementary Table S2). The kidneys appeared normal in most mice, except in some severely 
affected mice where small dark-red areas suggested incomplete perfusion (Supplementary 
Figure S2c left). 
Tissue specific expression of STOP78SER-APOA2 
In K and Y mice STOP78SER-APOA2 was solely expressed in liver and intestine (Figure 3). In F 
mice, STOP78SER-APOA2 was highly expressed in liver and intestine, but also ectopically in 
kidney and, very little, in stomach. This ectopic expression may stem from random insertion of 
the transgene in the genome of the F founder mouse near a kidney-specific promoter and/or 
enhancer. Thus, K mice with physiological plasma STOP78SER-ApoAII concentration are good 
models of hereditary systemic amyloidosis since STOP78SER-ApoAII is not synthesized in 
kidney, heart, spleen and stomach that have substantial amyloid deposits. F mice also display 
systemic amyloidosis in heart and spleen that do not synthesize STOP78SER-ApoAII, whereas in 
kidney endogenous STOP78SER-ApoAII production may contribute to amyloid deposits. 
Characterization of the amyloidogenic protein: 
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A)  At the nucleotide and amino acid levels 
DNA sequencing verified the nucleotide sequence of full-length mature STOP78SER-APOA2 
(Supplementary Figure S3). Biochemical characterization of the amyloid fibril protein yielded 
the amino acid sequence of full-length mature STOP78SER-ApoAII (without the pre- and 
propeptides) including the 21 amino acid carboxyl-terminal extension. Two amino acid residues 
differed from normal apoAII: Ser59 (replacing Glu59) resulted from the generation of a SpeI site 
in Exon 4 (cf. Supplementary Methods), and Leu64 by Phe most likely from a polymerase chain 
reaction (PCR) anomaly during production of the transgene construct. Neither Glu59 nor Leu64 
are conserved amino acids in apoAII of humans, primates, mice and rats. The presence of Ser59 
and Phe64 in a different hApoAII mutant did not result in amyloidosis (A.D. Kalopissis and M. 
Chabert, data not shown), showing that neither amino acid was implicated in amyloidogenesis. 
Therefore, amyloidosis in our STOP78SER-ApoAII transgenic mice was related to the carboxyl 
terminal extension, which is the cause of the human disease. 
B) By Proteomic analysis 
Full-length mature hApoAII including the STOP to Serine mutation and the 21 amino acid 
carboxyl-terminal extension was identified in amyloid deposits of kidneys, liver, heart and spleen 
of an F mouse (Table 1), with sequence coverage from 68 to 91% (Supplementary Figure S4). 
Comparably to human amyloidoses5,6, considerable amounts of apoE and lower amounts of 
vitronectin, clusterin, complement C3, apoB100, apoCIII, and apoAI were present in the deposits, 
but SAP was absent. Neither fibril-AApoAII nor fibril-associated proteins were detected in 
corresponding areas of Y mice. 
Histochemistry 
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The amyloid deposits were consistently extracellular and stained with CR (Figure 1a,b) with a 
typical red-green birefringence observed under polarized light (Figure 1aPol.). The most affected 
organs were the kidneys, liver, heart, and spleen. Amyloid deposits were: i) abundant in kidney 
glomeruli and intertubular spaces of the F mouse, and in glomeruli of the K mouse; ii) greater in 
the liver of the F compared with the K mouse, disorganizing the plates of hepatocytes. The renal 
medulla was totally devoid of amyloid deposits in F and K mice (Supplementary Figure S5). 
Amyloidosis was never detected in any organ of Y mice (Figure 1c). Figure 2 shows extensive 
amyloid deposits in the F mouse, in the adrenal gland, stomach, duodenum, jejunum and ileum, 
and less abundant in the colon. The brain, eyes, salivary gland, lung, urinary bladder, striated 
muscle and testicle were devoid of amyloid fibrils, as was the ovary (not shown). The absence of 
amyloid in testicles and ovaries may explain the normal fertility of transgenic mice. 
Immunohistochemistry 
Figure 4 illustrates the increase in amyloid burden with age in K and F mice. In young mice part 
of STOP78SER-ApoAII (green, Figure 4a) was internalized at the apical surface of kidney 
proximal tubules, and part already deposited as amyloid in glomeruli and peritubular spaces 
(Figure 4a,c). Indeed, normal apoAII34 and apoAI34,35 are internalized in proximal tubules and 
degraded in lysosomes. At the intermediate and advanced stages, STOP78SER-ApoAII was not 
reabsorbed but formed great aggregates in glomeruli and peritubular spaces (Figure 4a,c,d). In Y 
mice STOP78SER-ApoAII was not retained in glomeruli and was internalized in proximal 
tubules; the little immunostaining is due to the very low STOP78SER-ApoAII concentration 
(Figure 4b).  
Interestingly, mouse apoAI (mApoAI, red) was internalized at the apical surface of proximal 
tubules at the early (mice F1 and F2, Figure 4c) and little in advanced stage (mouse F3, Figure 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
 10
4d), whereas in some severely affected mice mApoAI was not internalized (mice F4 and F5, 
Figure 4d). 
At the early stage, very little amyloid deposited extracellularly along hepatocytes, 
cardiomyocytes, and spleen capillaries (Figure 4a). At the intermediate stage, amyloid deposits 
were present along large hepatic vessels and smaller ones; they were abundant between 
cardiomyocytes but scarce along spleen capillaries. At the advanced stage, the liver, heart and 
spleen were filled with amyloid deposits. 
To ascertain that amyloidosis was solely due to the STOP to Serine mutation of hApoAII, parallel 
analyses were conducted in transgenic mice with high plasma levels of either hApoAII (Lambda, 
λ, line30,36) or STOP78SER-ApoAII (F line). Human apoAII is synthesized in the liver of λ 
mice30, catabolized in the kidney34, and present in punctate form suggesting vesicular transport. 
In λ mice which never develop amyloidosis, hApoAII: was not retained in kidney glomeruli but 
was internalized at the apical surface of proximal tubules, essentially in the S1 segment adjacent 
to glomeruli (Figure 5a); was totally absent in the heart (Figure 5b); was present in the 
endoplasmic reticulum of hepatocytes near nuclei and secreted in the space of Disse (Figure 5c); 
was little present along some spleen capillary membranes (Figure 5d). In F mice STOP78SER-
ApoAII formed thin/thick lines suggesting aggregates, and: accumulated in kidney glomeruli and 
intertubular spaces, and was not internalized in proximal tubules (Figure 5a); deposited 
extracellularly between cardiomyocytes and endothelial cells, forming thin or thick lines (Figure 
5b); was not detected in hepatocytes but formed thick lines in the space of Disse (Figure 5c); 
formed abundant aggregates in extravascular spaces of the spleen red pulp (Figure 5d). The liver 
and spleen with extensive amyloid deposits became greatly enlarged due to their abundant 
capillary networks. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
 11
Electron microscopy 
In the K mouse extensive amyloid fibrils accumulated extracellularly disorganizing capillary 
structure (Figure 6a). The fibrils accumulated in: kidney glomeruli, between endothelial cells of 
capillaries and podocytes, and in intertubular spaces; the space of Disse of the liver, between 
hepatocytes and endothelial cells; the heart, between cardiomyocytes and endothelial cells; the 
extravascular space of the spleen red pulp. These organs were devoid of amyloid deposits in Y 
mice (Figure 6b). We observed typical fibrils of indeterminate length, approx. 10 nm in 
diameter, composed of twisted protofibrils1-4 (Supplementary Figure S6).  
Kidney dysfunction 
Y mice displayed normal renal function (Figure 7). Creatinine was significantly increased in 
serum and decreased in urine of K and F mice, compared with C57BL/6 mice. In serum, urea was 
significantly higher in F mice, while in urine it was significantly decreased in F and K mice 
compared with wild-type ones. Urinary protein concentration was significantly lower in F and K 
mice versus wild-type ones. Finally, the protein/creatinine ratio was significantly lower only in 
serum of F mice. Thus, glomerular amyloidosis provoked renal insufficiency as in the human 
disease, at ages above 6 and 5 months for K and F mice, respectively. 
Low-grade inflammation 
Because amyloidosis causes renal insufficiency often accompanied by inflammation37, we 
measured two plasma inflammation markers, CCL2/MCP1 and CXCL1/KC (Table 2). Both 
markers were significantly increased in K, F, and even in Y mice, as compared with mice without 
amyloidosis (KOAII, and lines β, δ, λ expressing APOA230,33,34,36). CCL2/MCP-1 is increased in 
hemodialysis patients, far above the values of Y, K, and F mice38. The low-grade inflammation of 
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K and F mice may be related to kidney dysfunction due to amyloidosis, and that of Y mice to the 
presence of STOP78SER-ApoAII. 
STOP78SER-ApoAII in plasma and high density lipoprotein 
Plasma STOP78SER-ApoAII did not decrease with age in Y mice, but drastically decreased in K 
and F mice (Figure 8), suggesting STOP78SER-ApoAII deposition into amyloid fibrils the 
amounts of which increased with age (Figure 4). 
Because apoAII is an apolipoprotein of high density lipoprotein (HDL), we analyzed HDL 
apolipoprotein compositions of five patients with AApoAII amyloidosis10-12. STOP78SER-
ApoAII conserves Cys6 and forms a 20 kDa-homodimer39 (Figure 9a,b). The patient’s HDL 
carried similar amounts of dimers 17 kDa-hApoAII and 18.5 kDa-STOP78SER-
ApoAII/hApoAII, but trace amounts of 20 kDa-STOP78SER-ApoAII. To determine whether 
STOP78SER-ApoAII has a diminished lipid binding capacity, we analyzed HDL-STOP78SER-
ApoAII contents of K and F mice aged 4 to 7 months (Figure 9c). In young K mice, HDL carried 
high STOP78SER-ApoAII amounts, whereas in 7-month-old mice STOP78SER-ApoAII 
decreased and apoAI was the major apolipoprotein, as in normal humans and mice. In F mice 
aged 4 and 5 months, HDL carried high STOP78SER-ApoAII amounts, whereas at 6 and 
especially 7 months, STOP78SER-ApoAII decreased and apoAI was the major apolipoprotein. 
The observation that HDL of young K and F mice carried high amounts of STOP78SER-ApoAII 
clearly indicates that STOP78SER-ApoAII conserved adequate lipid binding properties. Thus, 
the age dependent decrease of STOP78SER-ApoAII in HDL (Figure 9) and serum (Figure 8) is 
probably related to preferential deposition of STOP78SER-ApoAII onto preformed amyloid 
fibrils. HDL of Y mice carried low STOP78SER-ApoAII amounts, as expected from its low 
plasma concentration (Figure 9b,d). 
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DISCUSSION 
We report a novel transgenic mouse model of human hereditary systemic amyloidosis due to 
circulating STOP78SER-ApoAII, with the kidneys the major affected organs. Amyloid fibrils 
deposited primarily in renal glomeruli and peritubular spaces but not in medullary interstitium, 
comparably to the human disease10-12 and unlike AApoCII13 and AApoAIV15 amyloidoses. Renal 
insufficiency was observed in transgenic mice at ages above 5-6 months. The physiological 
plasma STOP78SER-ApoAII concentration of hemizygous K mice was sufficient to induce 
amyloidosis, as in the human disease10-12. K mice express STOP78SER-APOA2 only in the liver 
and intestine, and not in the kidney, heart and spleen with heavy amyloid burden. Moreover, the 
amyloid fibril protein was the secreted form of full-length mature STOP78SER-ApoAII (without 
the pre- and pro-peptides), as in human patients10-12. Thus, K mice are an appropriate model of 
hereditary systemic amyloidosis. 
The deposits also contained fibril-associated proteins as in human biopsies (apoE, apoAI, 
apoCIII, apoB, vitronectin, clusterin) with the exception of SAP5,6. The role of these proteins is 
unknown, but they are not necessary for amyloidogenesis since mice deficient in SAP40, apoE41,42 
or apoAI42 develop amyloidosis. SAP is an acute phase reactant in mice43, and is indeed present 
in transgenic mice with high SAA expression24. The absence of SAP in amyloid fibrils of our 
STOP78SER-ApoAII-transgenic mice could stem from the lack of high inflammatory state. 
Indeed, our mice displayed low-grade inflammation (shown by the small elevation of 
inflammation markers CCL2/MCP1 and CXCL1/KC), possibly representing a compensatory 
response to amyloidosis. 
Patients with AApoAII amyloidosis have proteinuria, azotemia and finally renal failure, in the 
fifth/sixth decade10-12, but serum and urine parameters have been reported for very few patients. 
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In transgenic mice above 6 months of age, creatinine significantly increased in the serum and 
decreased in the urine, indicating onset of renal insufficiency. Notably, F mice with higher 
STOP78SER-APOA2 expression were more affected than K mice. However, transgenic mice did 
not display proteinuria, and urinary protein concentration was lower than in controls. A possible 
explanation is that glomerular filtration was progressively blocked by increasing amyloid 
deposits with age. This is corroborated by decreased internalization of apoAI in kidney proximal 
tubules in older mice, and absence of apoAI in two severely affected 7 month-old F mice (Figure 
4d). A limitation of this study is that our transgenic lines are congenic, not co-isogenic, to 
C57BL/6 due to backcrossing to the KOAII/C57BL6 background, and thus contain portions of 
chromosome 1, surrounding the targeted mouse Apoa2 locus, which are still 129S4/SvJae32,44-46. 
Therefore, we cannot exclude that passenger mutations may contribute to the kidney dysfunction 
of F and K mice. Furthermore, the four groups of mice were not totally matched in age, with a 
higher percentage of older mice in F and Y lines. 
The decrease in sera and HDL of STOP78SER-ApoAII as a function of age raised the question of 
a diminished lipid binding capacity. However, HDL of young K and F mice carried high 
STOP78SER-ApoAII amounts, the STOP78SER-ApoAII-HDL amount decreasing in older mice. 
Therefore, STOP78SER-ApoAII conserves adequate lipid binding capacity. Probably, part of 
newly secreted STOP78SER-ApoAII rapidly aggregates onto amyloid fibrils in young mice, 
while another part associates with HDL and remains in the circulation. Later in life, increasing 
amounts of newly secreted STOP78SER-ApoAII are preferentially driven into preformed fibrils, 
in accord with the “seeding process” theory. Similar decreases in the serum concentration of 
amyloidogenic apolipoproteins have been described in patients with hereditary systemic 
amyloidosis due to the variants apoAI-Iowa47 and apoCIII-D25V14. 
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The molecular mechanism(s) of amyloid formation and its determinants are largely unknown. An 
established concept is initiation of protein misfolding by short 4- to 10-residue segments, termed 
amyloid “hot spots”, with high propensity for β-aggregation. By use of the consensus prediction 
algorithm AMYLPREP248 hApoAII was shown to have two amyloid “hot spots” in residues 10-
18 and 60-7049. However, hApoAII is not amyloidogenic in humans and transgenic mice (Figure 
5). The additional “hot spot” in residues 79-87 of the C-terminal extension49 of STOP78SER-
ApoAII may trigger amylogenicity. Contrary to hApoAII, type C mApoAII is amyloidogenic in 
its mature and pro-apoAII forms in senescence-prone mice, with an autosomal recessive 
transmission17,18. Murine apoAII was predicted to have two major amyloid “hot spots” in residues 
6-16 and 48-6549. The difference in amyloidogenicity between mApoAII and hApoAII is 
unexplained at present. Interestingly, AApoAI8, AApoAII10-12,28,29, and AApoCIII14 amyloidoses 
are caused by some full-length variant proteins, or by peptides issued from some proteins by 
protease cleavage (i.e. several amino-terminal peptides of apoAI8,9, and the amino-terminal 
amino acid-peptide of SAA50). 
In conclusion, expression of STOP78SER-APOA2 with a carboxyl terminal, 21 amino acid 
extension is the obvious cause of amyloidosis in our transgenic mice. K mice display systemic 
amyloidosis, since STOP78SER-ApoAII is produced in the liver and intestine and not in tissues 
with great amyloid deposits such as kidney, heart and spleen, and amyloid deposits contain the 
secreted STOP78SER-ApoAII form. Despite ectopic STOP78SER-APOA2 expression in kidneys, 
F mice with higher plasma STOP78SER-ApoAII concentration develop amyloidosis early in life 
and may serve to test new therapeutic molecules. The absence of amyloidosis in low-expressing 
Y mice suggests a threshold for aggregation and fibrillogenesis, and justifies therapies using 
gene-silencing therapies to lower production of amyloidogenic proteins51,52. This novel mouse 
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model of hereditary systemic amyloidosis faithfully reproducing the human pathology10-12,28,29 
with the additional advantages of early onset of amyloidosis and great fertility should be very 
useful to researchers. Importantly, the great structural similarity of amyloid fibrils formed by all 
amyloidogenic proteins1-4 opens the way to usage of this model to study in vivo amyloid 
formation and to devise and test treatments for all amyloidoses. 
 
METHODS 
Generation and maintenance of transgenic mice 
The generation, maintenance and identification of the three transgenic lines Y, K and F are 
described in Supplementary Methods.  
The procedures followed were in accordance with institutional regulations for the care and use of 
laboratory animals. The Ethics Committee gave favorable opinions #Ce5/2012/028 and 
APAFIS#6010-2016070718347485 v3. All transgenic lines have been deposited at the 
MIGRATECH® database of Inserm (Institut National de la Santé et de la Recherche Médicale) 
with the following numbers: MT0564, Mouse models of Amyloidosis for STOP78SER-ApoAII-
transgenic mice, and MTO513, MTO502, MTO471, ApoA2-humanized transgenic mice. 
Amyloid fibril extraction and biochemical analysis of amyloid protein, Direct DNA Sequence 
Analysis, RNA extraction and Real time-polymerase chain reaction, Blood sampling and 
biochemical analyses, Immunohistochemistry, Electron microscopy 
See Supplementary Methods 
Tissue sampling and histological analyses 
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Following blood drawing, intracardiac vascular washing was performed with 20 ml 0.1 M 
phosphate buffer (PB) and then with 15 ml 4% paraformaldehyde (PFA) in 0.1 M PB. The tissues 
were quickly removed, rinsed in PB, and cut. 
Details for CR staining and immunohistochemistry are in Supplementary Methods. 
Mass spectrometry-based proteomic analysis 
Proteomic analyses were performed in kidney, liver, heart and spleen of one F and one Y mouse 
aged 7 months. Proteins were extracted from amyloid deposits identified by CR staining and laser 
microdissected. Tryptic peptides were separated by nano-liquid chromatography coupled to 
nanospray ionisation tandem mass spectrometry; proteins were identified by searching mouse 
protein database (SwissProt) with experimental data using Mascot. Search for STOP78SER-
ApoAII required that the sequence be incorporated into the database. The spectral count metric 
used to rank the proteins according to their relative abundance in the sample corresponds to the 
spectral count values from Proline software. 
Details are in Supplementary Methods 
Lipoproteins and apolipoproteins 
Lipoproteins were prepared from pooled sera from at least 10 mice/group, supplemented with 
0.005% gentamycin/1 mM EDTA/0.04% Na-azide, 0.02% merthiolate and protease inhibitors, 
and subjected to sequential ultracentrifugations53. Details of ultracentrifugation conditions, SDS-
PAGE and Western blotting of HDL from patients and transgenic mice are in Supplementary 
Methods. 
Statistical analysis 
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Statistical calculations were carried out using GraphPad Prism 5.02. The statistical tests used for 
each experiment are indicated in the legend of the corresponding table or figure. P values <0.05 
were considered statistically significant. 
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SUPPLEMENTARY MATERIAL 
Supplementary Methods 
Generation and maintenance of transgenic mice 
Amyloid fibril extraction and biochemical characterization 
Direct DNA sequence analysis 
RNA extraction and RT-PCR 
Blood and urine sampling and biochemical analyses 
Immunohistochemistry 
Electron microscopy 
Mass spectrometry-based proteomic analysis 
Lipoproteins and apolipoproteins 
Supplementary Figures 
Figure S1. Generation of pUC-APOA2 with the STOP to SER mutation. 
Step 1: Generation of pUC19-Exon 4 SpeI  
Step 2: Generation of pUC19-Exon 4 Stopless 
Step 3: Generation of full-length pUC19-STOP78SER-APOA2 
Abbreviation: E1 to E4: Exons 1 to 4.  
Figure S2. Macroscopic alterations of organs due to amyloidosis.  
The kidneys (K), liver (L), heart (H) and spleen (S) of 7 month-old wild-type C57BL/6 and 
hemizygous F mice were photographed following intracardiac washing. (a) The four organs from 
a C57BL/6 (left) and an F mouse (right). (b) The four organs from two F mice. (c) Enlargement 
of the kidneys of the two F mice in (b). Note that the liver, heart and spleen of transgenic mice 
were larger and the liver often distorted, as compared to the same organs of the wild-type mice. 
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In most cases, the kidneys of transgenic mice appeared normal, as in (a) and (b) on the right. In 
very few mice, one or both kidneys displayed small dark areas suggesting incomplete perfusion, 
as the left kidney in (b). 
Figure S3. Nucleotide and amino acid sequences of full-length AApoAII in amyloid 
deposits.  
The genomic DNA was extracted from splenic tissue and exons 3 and 4 of the AAPOA2 gene 
were directly sequenced. Amyloid fibrils were extracted from tissues of K and F mice and 
biochemically characterized. These analyses revealed the amino acid sequence of full-length 
AAPOA2 cDNA with the 21 amino acid carboxyl terminal extension. The protein sequence is 
presented in single letter code below each codon. Two amino acid residues differed from the 
normal hApoAII sequence: Glu59 was replaced by Ser59 by site directed mutagenesis in order to 
generate a SpeI site. The substitution of Leu64 by Phe64 was probably due to a PCR anomaly, 
which occurred during production of the transgenic construct. The STOP78 to SER mutation was 
obtained by generation of a restriction site for SacI, so that the STOP codon TGA was mutated to 
AGC coding for SER78, while CTC coded for the following SER79. 
The modified nucleotides are represented in blue, and the modified amino acids in red. The red 
lines indicate the tryptic peptides that were sequenced; the green lines are tryptic peptides found 
in the same digest and found to overlap the other sequences. The pre- and pro-peptide were not 
found in AApoAII of any amyloid deposits since they were cleaved by specific proteases: the 
prepeptide cotranslationally, and the propeptide just after secretionS1. 
Figure S4. Sequence coverage of AApoAII in proteomic analysis of amyloid fibrils.  
Mass spectrometry-based proteomic analyses were performed in kidney, liver, heart and spleen of 
one F and one Y mouse aged 7 months. An area of 150 000 µm2 of congophilic amyloid deposits 
was selected by laser microdissection for each organ of F mice. Y mice which do not develop 
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amyloidosis served as a control, and comparable areas were dissected from each organ. Proteins 
were extracted, digested into tryptic peptides, and separated by nano-liquid chromatography 
coupled to nanospray ionisation tandem mass spectrometry. The amino acid sequence of the pre- 
and pro-peptide of hApoAII and AApoAII (a total of 23 amino acids) is highlighted in turquoise, 
and was not taken into account for the calculation of the sequence coverage. Indeed, the pre- and 
pro-peptides are hydrolyzed by intracellular and extracellular proteases, respectively, and only 
the mature hApoAII (77 amino acids) or STOP78SER-ApoAII (98 amino acids) are secreted by 
hepatocytesS1. 
The 21 amino acid extension of AApoAII is highlighted in yellow, and the sequence coverage in 
red bold type.  
Figure S5. Absence of amyloid deposits in renal medulla.  
The kidneys were obtained from the same 7 month-old F, K and Y mice described in Figure 1. 
Ten µm-thick kidney sections were stained with Congo red (CR), counterstained with 
hematoxylin/eosin, and viewed by optical microscopy and under strong polarized light. 
Characteristic images of optical microscopy are shown. Images under polarized light were 
negative and are not shown. 
In the photomicrograph of the K mouse the cortex, medulla and papilla are indicated by dashed 
lines drawn across each area. 
C cortex; DT, distal tubule; H, loop of Henle; M, medulla; P, papilla; PT, proximal tubule 
Scale = 100 µm 
Figure S6. Typical amyloid fibrils in liver and spleen.  
The liver and spleen of the 7 month-old K mouse (shown in Figure 2) were viewed by electron 
microscopy at 10 000 magnification. Extracellular amyloid deposits appeared as rigid non-
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branching, randomly arranged fibrils ranging from 8 to 11 nm in external diameter. Fibrils were 
twisted and of indeterminate length. 
SUPPLEMENTARY TABLES 
Table S1. Amyloidogenic human apolipoprotein AII mutations 
Table S2. Classification of macroscopic alterations of organs from STOP78SER-ApoAII-
transgenic mice 
Supplementary material is linked to the online version of the paper at www.kidney-
international.org. 
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FIGURE LEGENDS 
Figure 1. Major amyloid deposits in kidney, liver, heart and spleen 
Several tissues were prepared from hemizygous 7 month-old mice (4 F, 4 K and 4 Y mice) as 
described in Methods under “Tissue sampling and biological analyses”. Macroscopically, the 
following stages were observed: i) F mice: heart 3 or 4, liver 4, spleen 4; ii) K mice: heart 2 or 3 
or 4, liver 3 or 4, spleen 3; iii) Y mice: heart 0, liver 0, spleen 0. As explained in Supplementary 
Figure S2, the kidneys of the above mice had a normal appearance: stage 0. 
Ten µm-thick sections of kidney, liver, heart, and spleen were stained with Congo red (CR), 
counterstained with hematoxylin/eosin, and viewed by optical microscopy and under strong 
polarized light (Pol.). Characteristic images of one F (heart 3, liver 4, spleen 4), one K (heart 3, 
liver 3, spleen 4), and one Y mouse are shown. (a) F mouse; (b) K mouse; (c) Y mouse, devoid 
of amyloid deposits. 
All photomicrographs contain scale bars. Arrowheads depict amyloid deposits. 
Figure 2. Amyloid deposits in several organs 
Ten µm-thick sections of organs from three 7 month-old F mice (the same as in Figure 1) and one 
K mouse (also studied in Figure 1), were stained with Congo red (CR), counterstained with 
hematoxylin/eosin, and viewed by optical microscopy. Characteristic images of one F mouse 
(heart 3, liver 4, spleen 4) are shown. (a) Organs with amyloid deposits; (b) Organs without 
amyloid deposits. 
All photomicrographs contain scale bars. Arrowheads depict amyloid deposits. 
Figure 3. Tissue specific expression of STOP78SER-APOA2 
Total RNA was extracted from 8 tissues of 4 month-old F, K, Y expressing STOP78SER-APOA2, 
and KOAII mice not expressing STOP78SER-APOA2. After reverse-transcription to cDNA, 
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STOP78SER-APOA2 cDNA was amplified by PCR. The length of PCR products is 177 bp, 
showing absence of contamination of mRNAs by genomic DNA. STOP78SER-APOA2 mRNAs 
are present in the liver and intestine of Y, K, and F mice, but not in tissues of KOAII mice used 
as negative controls. Ectopic expression of STOP78SER-APOA2 was detected in the kidney of F 
mice, and a very small one in the stomach. 
Figure 4. Aggravation of amyloidosis with age 
The kidneys, liver, heart and spleen were prepared from hemizygous F and K mice at ages 2, 5, 7 
or 8 months (three F and three K mice at each age), and from three 7 month-old Y mice. The 
tissue preparations are described in Methods under “Tissue sampling and biological analyses”. 
Macroscopically, the following stages were observed: i) 2 month-old F and 3 month-old K mice: 
heart 0, liver 0, spleen 0; ii) 5 month-old F mice: heart 2 or 3, liver 2 or 3, spleen 3; iii) 5 month-
old K mice: heart 1 or 2 or 3, liver 2 or 3, spleen 2 or 3; iv) 7 month-old F mice: heart 3 or 4, liver 
3 or 4, spleen 4; v) 7 month-old K mice: heart 2 or 3 or 4, liver 3 or 4, spleen 4; vi) 8 month-old F 
mice: heart 3 or 4, liver 4, spleen 4; vii) 8 month-old K mice: heart 3 or 4, liver 3 or 4, spleen 4; 
viii) 7 month-old Y mice: heart 0, liver 0, spleen 0. All kidneys studied had a normal appearance 
(see explanation in Supplementary Figure S2). 
Six µm-thick sections of kidney, liver, heart, and spleen of F and K mice were immunostained 
with: (a, c) anti-hApoAII specific antibody coupled to CY2 (green fluorescence); (b) anti-human 
apoAII antibody/CY2 (green fluorescence) and anti-mouse apoAI (mapoAI) antibody/CY3 (red 
fluorescence), and viewed by confocal microscopy. Representative images are illustrated. 
(a) “Early stage”: a 2-month old F mouse; “Intermediate stage”: a 5-6 month-old K mouse; 
“Advanced stage”: a 7 month-old F mouse; (b) kidney section of a 7 month-old Y mouse, devoid 
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of amyloid deposits; (c) kidney sections of two 2 month-old F mice (F1 and F2, early stage); (d) 
kidney sections of three 7 month-old F mice (F3, F4, F5, advanced stage). 
All photomicrographs contain scale bars. Arrows depict glomeruli, white arrowheads AApoAII 
(green), and yellow arrowheads mapoAI (red). 
Figure 5. Absence of amyloidosis in transgenic mice expressing normal human APOA2 
The kidneys, liver, heart and spleen were prepared from three 7 month-old transgenic F mice 
highly expressing STOP78SER-APOA2 and from three 7 month-old Lambda (λ) mice highly 
expressing APOA230,36. The tissue preparations are described in Methods under “Tissue sampling 
and biological analyses”. Macroscopically, the following stages were observed: i) λ mice: heart 
0, liver 0, spleen 0; ii) F mice: heart 3 or 4, liver 3 or 4, spleen 4. All kidneys studied had a 
normal appearance (see explanation in Supplementary Figure S2). 
Six µm-thick sections of kidney, liver, heart, and spleen of F and Lambda mice were 
immunostained with anti-hApoAII antibody (recognizing equally AApoAII and hApoAII) 
coupled to CY2 (green fluorescence) and viewed by confocal microscopy. Representative images 
are shown. 
(a) Kidney; (b) Heart; (c) Liver; (d) Spleen. 
All photomicrographs contain scale bars. Arrows depict glomeruli, white arrowheads AApoAII 
amyloid aggregates in K and F mice, and blue arrowheads hApoAII in Lambda mice. 
Figure 6. Electron microscopic analysis of amyloid deposits 
The kidney, liver, heart, and spleen from a 7 month-old K mouse (macroscopic stages: heart 4, 
liver 3, spleen 4, kidney 0), and a 7 month-old Y mouse (all macroscopic stages 0) were viewed 
by electron microscopy. Characteristic images are shown. (a) K mouse, two magnifications; (b) 
Y mouse, devoid of amyloid fibrils. 
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Because the scale bars under the photomicrographs are very small, we added the magnifications. 
Arrowheads depict amyloid deposits. 
Kidney: P, podocyte; PT, proximal tubule; C, capillary; MC, mesangial cell; E, endothelial cell; 
GBM, glomerular basement membrane; BS, Bowman space 
* Characteristic image of pedicell fusion 
Liver: SD, space of Disse; N, nucleus; M, mitochondrion; RER, rough endoplasmic reticulum; E, 
endothelial cell; SC, sinusoid capillary; G, glycogen; BC, bile canaliculus; ER, erythrocyte 
Heart: CM, cardiomyocyte; E, endothelial cell; M, mitochondrion; N, nucleus; PM, plasma 
membrane; BM, basement membrane; C, capillary 
Spleen: LC1, intravascular leucocyte; LC2, extravascular leucocyte; ΜΦ, extravascular 
macrophage; E, endothelial cell; C, capillary; ER1, intravascular erythrocyte; ER2, extravascular 
erythrocyte 
Figure 7. Kidney dysfunction is present in K and F transgenic mice 
Urea, creatinine, and total proteins were assayed in sera and urine of wild-type C57BL/6, F, K 
and Y mice. All transgenic mice were hemizygous. The protein/creatinine ratios were calculated 
in serum and urine, and the number of mice (n) used is shown under each genotype of the bottom 
graphic. The results were analyzed by the non parametric Kruskal-Wallis one-way ANOVA test. 
When a significant effect of the genotype on a variable was established, the non parametric 
Dunn’s multiple Comparison test was used to compare this variable between each transgenic line 
and the control C57BL/6 mice. The individual data of the four variables were presented in scatter 
dot plots, with different colors depending on the age of the mice: green for mice under 5 months 
of age; yellow for mice aged between 5 and 6 months; red for mice over 6 months of age. 
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Statistically significant differences between transgenic and wild-type mice are indicated by bars: 
* p< 0.05, ** p< 0.01, *** p< 0.001. 
C57, C57BL/6 mice. 
Figure 8. Decrease in serum STOP78SER-ApoAII concentration as a function of age and 
amyloid burden 
For each mouse, STOP78SER-ApoAII was assayed twice, at age one month and upon sacrifice at 
ages ranging from 2 to 10.5 months. Results were expressed as mean ± SD. Data were analyzed 
by the one phase decay non-linear regression. Data of F and K mice fitted the one phase decay 
non-linear regression model. STOP78SER-ApoAII of Y mice did not decrease with age. The 
number of mice used at each time point is indicated in parentheses. 
Figure 9. Biochemical characterization of STOP78SER-ApoAII in HDL of patients and 
transgenic mice 
HDL were isolated by ultracentrifugation from plasma of five patients with AApoAII 
amyloidosis and sera of transgenic mice. Patients carried either the STOP to Serine or the STOP 
to Glycine or the STOP to Arginine mutation10-12. (a) 15% SDS-PAGE and (b) Western blotting 
of human HDL using an anti-hApoAII antibody; (c) 15% SDS-PAGE of HDL of hemizygous K 
and F mice; (d) 15% SDS-PAGE of HDL of hemizygous and homozygous Y mice aged 5 
months. The same HDL-protein amount was deposited for all samples in the same gel (15 µg/lane 
in a, c, d and 6 µg/lane in b). 
(a) Lane 1, human HDL3 (H3); lane 2, Sd (LMW); lane 3, purified hapoAI (AI); lanes 4 to 8, 
patients 1 to 5; lane 9, purified hApoAII (AII). 
(b) Lane 1, Sd (LMW); lanes 2 to 6, patients 1 to 5; lane 7, purified hApoAII (AII); lane 8, HDL 
of Y mice carrying apoAI and STOP78SER-ApoAII. 
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(c) Lane 1, HDL from Lambda (λ) mice carrying essentially hApoAII30,36; lane 2, purified 
hapoAI (AI); lane 3, Sd (LMW); lanes 4 to 7, HDL from K mice aged 4, 5, 6, and 7 months, 
respectively; lanes 8 to 11, HDL from F mice aged 4, 5, 6, and 7 months, respectively; lane 12, 
Sd (LMW); lane 13, purified hApoAII (AII). 
(d) Lane 1, HDL from Lambda (λ) mice; lanes 2 and 3, HDL from homozygous and hemizygous 
Y mice, respectively; lane 4, purified hapoAI (AI); lane 5, Sd (RPN800V); lane 6, HDL from 
Beta (β) mice carrying hApoAII and apoAI30,36. 
The low molecular weight (LMW) standards (Sd) used were: i) LMW (Bio-Rad) corresponding, 
from top to bottom, to: 94, 66, 45, 31, 21.5, and 14.4 kDa; ii) RPN800V (Bio-Rad), 
corresponding, from top to bottom, to: 250, 160, 105, 75, 50, 35, 30, 25, 15, and 10 kDa. 
vApoAII: abbreviation for variant STOP78SER-ApoAII 
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Table 1. Proteomic analysis of amyloid deposits 
Accession number Description Gene 
name 
F mouse (MS/MS) Y mouse (MS/MS) 
Kidne
y 
Live
r 
Hear
t 
Splee
n 
Kidne
y 
Live
r 
Hear
t 
Splee
n 
sp|P08226|APOE_MOUSE Apolipoprotein E   Apoe 27 45 19 156 0 1 0 0 
sp|P02652m|APOA2m_HUMA
N 
STOP78SER-Apolipoprotein AII 
Human APOA2 8 16 7 30 0 0 0 0 
sp|P29788|VTNC_MOUSE Vitronectin   Vtn  13 6 12 3 0 0 0 0 
sp|Q06890|CLUS_MOUSE Clusterin   Clu  20 5 8 7 0 0 0 0 
sp|P01027|CO3_MOUSE Complement C3   C3  3 1 7 1 0 0 0 0 
sp|E9Q414|APOB_MOUSE Apolipoprotein B100   Apob  18 0 1 6 0 0 0 0 
sp|P33622|APOC3_MOUSE Apolipoprotein CIII   Apoc3  3 1 2 2 0 0 0 0 
sp|Q00623|APOA1_MOUSE Apolipoprotein AI   Apoa1  5 1 1 0 0 0 0 0 
sp|Q02566|MYH6_MOUSE Myosin-6   Myh6  0 0 193 0 0 2 175 0 
sp|Q91Z83|MYH7_MOUSE Myosin-7   Myh7  0 0 124 0 0 2 117 0 
sp|A2ASS6|TITIN_MOUSE Titin   Ttn  0 0 108 0 0 0 129 0 
sp|P60710|ACTB_MOUSE Actin, cytoplasmic 1   Actb  26 4 21 12 29 12 22 23 
sp|Q03265|ATPA_MOUSE ATP synthase subunit α, 
mitochondrial Atp5a1  15 0 42 0 23 19 26 3 
sp|P56480|ATPB_MOUSE 
ATP synthase subunit beta, 
mitochondrial   Atp5b  14 0 36 0 22 22 29 4 
sp|Q61292|LAMB2_MOUSE Laminin subunit beta-2   Lamb2  13 0 2 0 16 0 0 0 
sp|P01029|CO4B_MOUSE Complement C4-B   C4b  16 0 0 0 2 0 0 0 
sp|P68134|ACTS_MOUSE Actin, alpha skeletal muscle   Acta1  13 3 39 4 15 6 36 10 
sp|P57780|ACTN4_MOUSE Alpha-actinin-4   Actn4  0 6 18 0 17 1 4 2 
sp|P07724|ALBU_MOUSE Serum albumin   Alb  4 7 4 30 7 2 3 1 
sp|P01942|HBA_MOUSE Hemoglobin subunit α   Hba  2 2 2 30 5 2 2 9 
sp|P20152|VIME_MOUSE Vimentin   Vim  23 1 5 0 17 0 0 4 
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sp|P68372|TBB4B_MOUSE Tubulin beta-4B chain   Tubb4b  12 0 9 0 18 6 11 8 
sp|Q61001|LAMA5_MOUSE Laminin subunit α-5   Lama5  17 0 0 0 24 0 0 0 
sp|Q05793|PGBM_MOUSE 
Basement membrane-specific 
heparan sulfate proteoglycan core 
protein   
Hspg2  6 0 3 2 18 0 3 0 
sp|P10649|GSTM1_MOUSE Glutathione S-transferase Mu 1   Gstm1  2 5 6 0 8 10 3 0 
sp|P02088|HBB1_MOUSE Hemoglobin subunit beta-1   Hbb-b1  1 3 1 14 7 2 1 5 
sp|Q8C196|CPSM_MOUSE Carbamoyl-phosphate synthase [ammonia], mitochondrial   Cps1  0 4 0 0 0 67 0 0 
sp|Q8VDD5|MYH9_MOUSE Myosin-9   Myh9  8 0 0 1 26 2 0 10 
 
Congophilic areas of the kidney, liver, heart and spleen of one F and similar areas of one Y mouse aged 7 months were subjected to mass 
spectrometry-based proteomic analysis. Proteins were identified by searching mouse SwissProt database. To identify amyloid fibril AApoAII, the 
sequence of the human APOA2 with the STOP78 to Serine mutation was incorporated into the database. Notably, proteins typical of a given 
tissue were identified in both F and Y mice (myosin-6, myosin-7, and titin in the heart; laminin subunit a-5 in the kidney). 
MS/MS, number of total peptide spectra identified for each protein, corresponding to their relative abundance in the samples.  
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Table 2. Increase in serum inflammation markers in transgenic mice expressing STOP78SER-APOA2 
 
  no hApoAII  normal hApoAII  STOP78SER-ApoAII  
  KOAII   BETA (β) DELTA (δ) LAMBDA (λ)  Y K F  
CCL2/MCP-1 
(pg/ml) 
56 ± 4 
(15) a 
 69 ± 8 
(15) a 
77 ± 12 
(15) a 
67 ± 5 
(15) a  
163 ± 18 
(10) b 
170 ± 12 
(30) b 
233 ± 19 
(29) b 
CXCL1/KC 
(pg/ml) 
136 ± 18 
(15) a 
 129 ± 16 
(15) a 
148 ± 28 
(15) a 
163 ± 27 
(15) a  
237 ± 78 
(8) a, c 
249 ± 31 
(30) a, c 
319 ± 24 
(29) b, c 
hApoAII 
(mg/dl) 0 
 21.1 ± 1.14 
(13) a 
43.8 ± 4.4 
(12) a, c 
63.5 ± 6.9 
(12) b, c 
 22.5 ± 1.6 
(10) a 
52.9 ± 1.9 
(27) b, c 
65.2 ± 2.6 
(27) b, c 
Both cytokines, hApoAII and STOP78SER-ApoAII have been assayed in the serum of fed mice. The apoAII-deficient mice (KOAII) have been 
described in reference 32 and the transgenic lines β, δ, λ expressing normal APOA2 in references 30 and 36. Data are presented as Mean ± 
S.E.M. with the number of mice in parentheses. All data sets were verified for Gaussian distribution. Because Bartletts's test showed that 
variances differed significantly, we used the non-parametric Kruskall and Wallis's one way Anova test that established a significant effect of the 
genotype (p<0.0001) on each metabolic variable (CCL2, CXCL1, hApoAII and STOP78SER-ApoAII). We then used the non-parametric Dunn's 
test for post-hoc multiple comparisons between groups. For each variable: two data sharing at least one letter are not statistically different; two 
data not sharing the same letter are statistically different (at least p<0.05). 
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KOAII mice, mice deficient in endogenous apoAII; CCL2, Chemokine Ligand 2, also named MCP-1, Monocyte Chemoattractant Protein 1; 
CXCL1, Chemokine (C-X-C motive) Ligand 1, also named KC in mice. 
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CONCLUSION:
Systemic amyloidosis:
vApoAII, produced by liver and 
intestine, forms amyloid deposits in 
most organs (shown: heart, spleen)
A transgenic mouse model reproduces human hereditary systemic 
amyloidosis
Novel transgenic model, ideally suited to 
devise and test novel therapies for 
hereditary systemic amyloidoses
Chabert et al, 2019
Transgene: vApoAII
the amyloidogenic variant of 
human apolipoprotein AII with
the STOPSer mutation
Y low expression
Arrows: glomeruli
x 1000
Amyloid deposits in kidney glomeruli cause kidney dysfunction 
Congo red staining
(polarized light)
vApoAII (immuno-
histochemistry)
Electron microscopy
M
PM
BM
CM
x 10 000
Heart
ER1
ER2
LC2
LC1
LC1
E
E
x 1000
Spleen
Arrowheads: 
amyloid deposits
No amyloidosis
F
K
high expression:
onset at 2-3 months
normal expression:
onset at 3-4 months
Spontaneous development of 
amyloidosis as a function of 
vApoAII expression level and 
age of the mice
Transgenic lines:
